OR WAIT null SECS
August 09, 2022
Article
New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.
July 30, 2022
Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.
July 20, 2022
An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
July 07, 2022
A study of more than 15,000 patients from a national insurance research database suggests older patients with hypothyroidism had an 81% increase in risk of having dementia compared to their counterparts without hypothyroidism.
June 20, 2022
Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.
June 01, 2022
Dr. Gregory Weiss examines a recent study that detailed the risk of cardiovascular disease associated with under- and over-treatment with thyroid hormone therapy.
May 28, 2022
Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.
May 13, 2022
A systematic review and meta-analysis from AACE 2022 provides an overview of the potential associations between thyroid dysfunction, including both hypothyroidism and hyperthyroidism, and risk of Parkinson disease.
May 12, 2022
Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.
April 27, 2022
A retrospective cohort study provides evidence suggesting higher TSH levels were linked to increased lengths of stay and greater readmission risks among patients with hypothyroidism.
